Dusan Bogunovic, PhD
img_Dusan Bogunovic
PROFESSOR | Oncological Sciences
PROFESSOR | Microbiology
PROFESSOR | Dermatology
PROFESSOR | Pediatrics
Research Topics
Cellular Immunity, Cytokines, Gene Regulation, Gene Therapy, Genetics, Genomics, Human Genetics and Genetic Disorders, Immune Antagonism, Immune Deficiency, Immunological Tolerance, Immunology, Immunosuppression, Infectious Disease, Inflammation, Interferon, Lymphocytes, Viruses and Virology
Multi-Disciplinary Training Area
Development Regeneration and Stem Cells [DRS], Microbiology [MIC]
Lab Website
Human Immunogenetics
The Bogunovic lab focuses on the study of human immunogenetics. We aim to improve understanding of the human immune system by studying: 1) Individuals with rare auto-inflammatory syndromes. 2) Individuals with severe clinical presentations of infectious diseases. 3) Developing broad spectrum antiviral therapeutics. 4) Understanding immune system in Down syndrome. To dissect these phenotypes and develop therapeutics we use genomic, genetic, molecular biology, cellular biology, immunology and clinical tools. The hypothesis of the lab is that inter-individual variability in immune responses (in auto-inflammatory syndromes and infections) can also be explained by the immune genetic composition of the host. We aim to illuminate the elusive pathogenesis of these diseases, hoping to lay the foundation for a novel and paradigm-shifting approach to the rational design of both preventative medicine (vaccines and genetic counseling) and treatments beyond currently used antimicrobials.

PhD, New York University Medical School

Postdoctoral Fellow, The Rockefeller University


Hirschl Scholar Award

Icahn School of Medicine at Mount Sinai


Quickfire Challenge Winner

Johnson and Johnson


Lamport Research Award

Icahn School of Medicine at Mount Sinai


Young Investigator Award

American Society for Microbiology


Milstein Award for Young Investigators

International Cytokine and Interferon Society


Selected Publications

Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19. Daniela Matuozzo, Estelle Talouarn, Astrid Marchal, Peng Zhang, Jeremy Manry, Yoann Seeleuthner, Yu Zhang, Alexandre Bolze, Matthieu Chaldebas, Baptiste Milisavljevic, Adrian Gervais, Paul Bastard, Takaki Asano, Lucy Bizien, Federica Barzaghi, Hassan Abolhassani, Ahmad Abou Tayoun, Alessandro Aiuti, Ilad Alavi Darazam, Luis M. Allende, Rebeca Alonso-Arias, Andrés Augusto Arias, Gokhan Aytekin, Peter Bergman, Simone Bondesan, Yenan T. Bryceson, Ingrid G. Bustos, Oscar Cabrera-Marante, Sheila Carcel, Paola Carrera, Giorgio Casari, Khalil Chaïbi, Roger Colobran, Antonio Condino-Neto, Laura E. Covill, Ottavia M. Delmonte, Loubna El Zein, Carlos Flores, Peter K. Gregersen, Marta Gut, Filomeen Haerynck, Rabih Halwani, Selda Hancerli, Lennart Hammarström, Nevin Hatipoğlu, Adem Karbuz, Sevgi Keles, Dusan Bogunovic, Yuval Itan, Nadjib Hammoudi. Genome Medicine

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia. Quentin Philippot, Arnaud Fekkar, Adrian Gervais, Tom Le Voyer, Leonoor S. Boers, Clément Conil, Lucy Bizien, Justin de Brabander, Jan Willem Duitman, Alessia Romano, Jérémie Rosain, Marion Blaize, Mélanie Migaud, Maxime Jeljeli, Boualem Hammadi, Aurore Desmons, Astrid Marchal, Esther J. Nossent, Anno Saris, Heder De Vries, Lilian J. Meijboom, Siebe G. Blok, Alex R. Schuurman, Tom D.Y. Reijnders, F. Hugenholtz, Juan J.Garcia Vallejo, Hetty Bontkes, Alexander P.J. Vlaar, Joost Wiersinga, René Lutter, Tom van der Poll, Harm Jan Bogaard, Robert F.J. Kullberg, Shiqi Zhang, Esther J. Nossent, Leo M.A. Heunks, Pieter Roel Tuinman, Peter I. Bonta, Laurent Abel, Saleh Al-Muhsen, Andrés A. Arias, Dusan Bogunovic, Alexandre Bolze, Ahmed A. Bousfiha, Davood Mansouri, Isabelle Meyts, Rebeca Perez de Diego, Vanessa Sancho-Shimizu, András N. Spaan, Stuart G. Tangye. Journal of Clinical Immunology

Erratum: Mapping Systemic Inflammation and Antibody Responses in Multisystem Inflammatory Syndrome in Children (MIS-C) (Cell (2020) 183(4) (982–995.e14), (S0092867420312319), (10.1016/j.cell.2020.09.034)). Conor N. Gruber, Roosheel S. Patel, Rebecca Trachtman, Lauren Lepow, Fatima Amanat, Florian Krammer, Karen M. Wilson, Kenan Onel, Daniel Geanon, Kevin Tuballes, Manishkumar Patel, Konstantinos Mouskas, Timothy O'Donnell, Elliot Merritt, Nicole W. Simons, Vanessa Barcessat, Diane M. Del Valle, Samantha Udondem, Gurpawan Kang, Charuta Agashe, Neha Karekar, Joanna Grabowska, Kai Nie, Jessica Le Berichel, Hui Xie, Noam Beckmann, Sandeep Gangadharan, George Ofori-Amanfo, Uri Laserson, Adeeb Rahman, Seunghee Kim-Schulze, Alexander W. Charney, Sacha Gnjatic, Bruce D. Gelb, Miriam Merad, Dusan Bogunovic. Cell

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Bogunovic during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Company Founder:

  • Lab11 Therapeutics

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Lab11 Therapeutics Inc

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.